Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and effectiveness of Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Posterior Advanced Non-small Cell Lung Cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yongchang Zhang
• Treatments: Apatinib; Vinblastine; Vinorelbine

Criteria

Inclusion Criteria:

• 18，Pathologically proven non small cell lung cancer

• Adenocarcinoma，No-drive gene mutaion (EGFR、ALK、ROS1） by NGS

• Squamous cell carcinoma，no gene detection

• Progress after second line

• PS score >2

Exclusion Criteria:

• Patients received apatinib or Vinorelbine treatment before

• EGFR, ALK or ROS1 mutation

• Patients with contraindication of chemotherapy

• Pregnant or breast feeding women